Evidence map›Paper›PMID 40831883›Full record

ArticleLiver cancer2025

High Frequency of

Athanasios Tyraskis, Yoh Zen, Sandra Strautnieks, Riley Cook, Pierre Foskett, Claudio De Vito, Maesha Deheragoda, Alberto Quaglia, Nigel Heaton, Mark Davenport and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Liver cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Athanasios TyraskisInstitute of Liver Studies, King's College London, London, UK.
Yoh ZenInstitute of Liver Studies, King's College Hospital, London, UK.
Sandra StrautnieksInstitute of Liver Studies, King's College Hospital, London, UK.
Riley CookDepartment of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK.
Pierre FoskettInstitute of Liver Studies, King's College Hospital, London, UK.
Claudio De VitoDivision of Clinical Pathology, Geneva University Hospital, Geneva, Switzerland.
Maesha DeheragodaInstitute of Liver Studies, King's College Hospital, London, UK.
Alberto QuagliaDepartment of Cellular Pathology, Royal Free Hospital, London, UK.
Nigel HeatonInstitute of Liver Studies, King's College Hospital, London, UK.
Mark DavenportDepartment of Paediatric Surgery, King's College Hospital, London, UK.
Richard J ThompsonInstitute of Liver Studies, King's College London, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Patients born with congenital porto-systemic shunts have been shown to have a high risk of benign and malignant liver tumors in otherwise healthy livers. This study aimed to evaluate the genetic landscape of liver tumors in patients with congenital porto-systemic shunts (CPSS) and correlate genotype with histological findings. Methods: Nodules from patients with CPSS and sporadic pediatric focal nodular hyperplasia (FNH) or FNH-like nodules were evaluated histologically and sequenced for a panel of 50 genes using next-generation sequencing. Results: Thirty-eight nodules from 17 patients with CPSS were histologically classified as hepatoblastomas ( Discussion: CPSS is strongly associated with nodules containing variants in

Indexed as

Abernethy malformationCongenital porto-systemic shuntFocal nodular hyperplasiaHepatoblastomaHepatocellular adenomaHepatocellular carcinoma

Identifiers

PMID40831883
PMCPMC12360745

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.